NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Hemab Therapeutics Holdings, Inc. (COAG) Stock Analysis

Hemab Therapeutics Holdings, Inc. (COAG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

COAG

$35.34

+$1.17 (+3.42%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COAG with… →

COAG Key Statistics

As of Oct 21, 2026
Trading
Open
$34.17
Previous Close
$34.17
Day's Range
34.13–36.33
52-Week Range
23.00–55.42
Volume
388.26K
Valuation
Market Cap
$1.60B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.33
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$63.91M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
46.71M
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
460.45K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Hemab Therapeutics Holdings, Inc. (COAG) has a market capitalization of $1.60B.

In fiscal 2025, COAG reported revenue of $0.00.

COAG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$63.91M—
2024$0.00−$48.71M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$70.12M−$63.91M—
2024$0.00—−$50.38M−$48.71M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Hemab Therapeutics Holdings, Inc. (COAG) carries a market capitalisation of $1.60B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 59 employees.

COAG last closed at $35.34 on October 21, 2026. That is +$1.17 (+3.42%) against the previous close. Over the past 52 weeks the price has ranged from $23.00 to $55.42. The latest close sits 53.65% above that 52-week low.

Financial Health

In fiscal 2025, Hemab Therapeutics Holdings, Inc. reported revenue of $0.00. The same year closed with a net loss of $63.91M. Earnings per share on a trailing basis come to −4.33.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

No dividend is on file for COAG.

2026 is still running; the total return is +3.94% year to date.

Peer Comparison

Hemab Therapeutics Holdings, Inc. (COAG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Hemab Therapeutics Holdings, Inc. COAG $1.60B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Hemab Therapeutics Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Visit website →